Trial reportDrug design, development and therapy2025
Adverse Effects of Alfentanil versus Nalbuphine in Decompensated Cirrhotic Patients Undergoing Painless Gastroscopy: A Double-Blind, Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Opioid type, rather than liver function, is associated with postoperative nausea and vomiting after painless gastroscopy in decompensated cirrhosis.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare nalbuphine versus alfentanil combined with etomidate-propofol for safety and efficacy during painless gastroscopy in decompensated cirrhosis patients. Methods: One hundred and seventy-five advanced cirrhosis patients were randomized to receive Nalbuphine (0.1 to 0.15 mg·kg Results: The complication rates were 37.21% for nalbuphine and 11.24% for alfentanil group within 48 hours, exhibited a significantly difference ( Conclusion: Alfentanil demonstrates fewer postoperative complications and faster recovery than nalbuphine, potentially making it preferable for painless gastroscopy in decompensated cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.